The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer

A Randomized, Double Blinded, Parallel-controlled, Multi-center Phase II/III Study to Compare the Best Support Care (BSC) Plus K-001 Versus BSC Plus Placebo for the Third-line and Later Treatment of Patients With Advanced Pancreatic Cancer

No Standard therapy has been approved for third-line therapy of advanced pancreatic cancer. K001 is peptidoglycan prepared from the marine microorganism, with an anti-tumor activity. Previously, the phase I study of K001 has shown that K001 was safety and had some effectiveness for pancreatic patients. Now, we would like to lunch a randomized, blinded, parallel-controlled, multi-center phase II/III study to compare the best support care (BSC) plus K-001 versus BSC plus placebo for the third-line and later treatment of patients with advanced pancreatic cancer.

Study Overview

• Status: Unknown
• Conditions: Pancreatic Cancer
• Intervention / Treatment: Drug: K-001; Other: placebo

• Study Type: Interventional
• Enrollment (Anticipated): 600
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Xinlei Gong, MD; Phone Number: 86-25-80864049; Email: xinleigong@medmail.com.cn

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200127
      • Recruiting
      • RenJiH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Older than 18 years.
2. Metastatic or locally advanced pancreatic ductal adenocarcinoma which is confirmed by primary and/or metastatic pathology/cytology examination.
3. Had received at least 2 lines chemotherapy regimen, and the disease is progression or the toxicity could not be tolerated.
4. At least 28 days after the last chemotherapy.
5. Had a disease status that was measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version1.1).
6. Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.
7. Adequate hepatic, renal, and hematologic functions (neutrophils ≥1.5×10^9/L, platelets ≥ 80×10^9/L,hemoglobin ≥90g/L, total bilirubin within 2.0×the upper limit of normal(ULN), albumin≥30g/L, and ALT and AST≤3×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN and creatinine clearance rate > 30ml/min (Cockcroft-Gault).
8. For women of child-bearing age, the pregnancy test results (serum or urine) within 14 days before enrolment must be negative. They will take appropriate methods for contraception during the study until the 60 days post the last administration of study drug. For men (previous surgical sterilization accepted), will take appropriate methods for contraception during the study until the 60 days post the last administration of study drug.
9. Signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure

Exclusion Criteria:

1. Patients is not confirmed by pathology/cytology examination as pancreatic ductal adenocarcinoma.
2. Target lesions were once treated locally and does not exhibit progression recently.
3. Patients with already diagnosed central nervous system metastasis. Patients with clinical symptoms of central nervous system metastasis should be examined by MRI.
4. Patients with Vater 's ampullary carcinoma or biliary adenocarcinoma.
5. Subject with partial or complete intestinal obstruction,or complete biliary obstruction who are unable to be relieved by active treatment
6. Subject has more than an average of intra-abdominal effusion, or the intra-abdominal effusion could not be control in 2 weeks.
7. Subject has a second malignancy other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers treated with curative intent and no known active disease within 5 years before planned start of study therapy.
8. Female subjects who are pregnant, planning a pregnancy or breast feeding during the study.
9. Subject has an active infection, or a hypertension could not be controlled by drugs, or angina diagnosed within 3 months, or unstable angina pectoris, or myocardial infarction diagnosed within 1 year, or with congestive heart failure (New York Heart Association [NYHA] Class II or III or IV), or with schizophrenia, or with the history of psychotropic substance abuse.
10. Subject has an active infection of hepatitis B (HBV), hepatitis C (HCV) or human immunodeficiency virus (HIV).

11. Subject has received any of the following treatment within the framework of a specific time frame prior to entry:

    1. received operation greater than grade II within 4 weeks;
    2. received extended range radiotherapy within 4 weeks, or locally radiotherapy within 2 weeks;
    3. participated in other therapeutic/interventional clinical trials within 4 weeks;
    4. received locally anti-tumor therapy within 4 weeks；
12. All toxic effects of any prior antitumor therapy resolved to Grade < 2 before the start of study therapy (with the exception of alopecia and pigmentation of skin).
13. Subject has known to be allergic or intolerant to K-001 and its excipients.
14. Other situations that the researchers considered inappropriate for inclusion in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Best Support Care Plus K-001; Best support care including analgesic treatment, anti-infection therapy, biliary obstruction treatment, nutritional support, psychological support, reasonable advice from physicians, good communication with patients and etc. K-001 9,720mg per day which means that take K-001 capsule 18 tablets (270mg per tablet) orally twice a day (morning and evening), 56 days as a cycle.	Drug: K-001; K-001 is an antitumor active substance (peptidoglycan) which is prepared from the fermentation product of marine microorganism. K-001 is the Chinese first class new drug and get patent licensing in China, America and Japan.
PLACEBO_COMPARATOR: Best Support Care Plus placebo; Best support care is the same as experimental arm. Placebo is take 18 placebo tablets which is the same as K-001 in appearance orally twice a day (morning and evening), 56 days as a cycle.	Other: placebo; Placebo which looks the same as K-001 in apparence; Other Names: K-001 placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
overall survival	The overall survival (OS) of the two groups of FAS was compared. FAS including all the subjects who take at least one dose of the research drug. All the subjects received tumor assessment every 8weeks according to RECIST1.1.	6 months after the last subject is enrolled

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PFS	All the subjects received tumor assessment every 8weeks according to RECIST1.1 to evaluate the progression-free survival (PFS) .	6 months after the last subject is enrolled
TTP	All the subjects received tumor assessment every 8weeks according to RECIST1.1 to evaluate the time to progression (TTP).	6 months after the last subject is enrolled
ORR	All the subjects received tumor assessment every 8weeks according to RECIST1.1 to evaluate the objective response rate (ORR).	6 months after the last subject is enrolled
DCR	All the subjects received tumor assessment every 8weeks according to RECIST1.1 to evaluate the disease control rate (DCR).	6 months after the last subject is enrolled
CBR	According to a questionaire to evaluate the clinical benefit response (CBR) of the two groups.	6 months after the last subject is enrolled
QOL	According to a questionaire to evaluate the quality of life (QOL) of the two groups.	6 months after the last subject is enrolled

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor marker	blood test to evaluate change of tumor markers, including CEA, CA19-9, CA125, CA724, AFP and etc. of the two groups	6 months after the last subject is enrolled
Hematology Index	blood test to evaluate change of D-Dimer, C-Reactive protein (CRP), Albumin (ALB), CAR (CRP/ALB) of the two groups	6 months after the last subject is enrolled

Collaborators and Investigators

• Sponsor: RenJi Hospital
• Investigators: Principal Investigator: Liwei Wang, Professor, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Principal Investigator: Shukui Qin, Professor, Nanjing Bayi Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 26, 2017
• Primary Completion (ANTICIPATED): March 1, 2021
• Study Completion (ANTICIPATED): March 1, 2021

Study Registration Dates

• First Submitted: November 25, 2019
• First Submitted That Met QC Criteria: November 28, 2019
• First Posted (ACTUAL): December 3, 2019

Study Record Updates

• Last Update Posted (ACTUAL): November 12, 2020
• Last Update Submitted That Met QC Criteria: November 9, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms
• Other Study ID Numbers: CPOG001-05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No